$ADMA Fraud Alert: ADMA Biologics Investors Sue for Recovery in Securities Fraud Class Action after 29% Stock Drop – Investors Notified to Contact BFA Law
Summary
ADMA Biologics faces a securities fraud class action after a sharp stock decline tied to short-seller allegations about channel stuffing and undisclosed related-party transactions. The complaint claims the company overstated 2025 growth and misled investors about demand for its flagship product, ASCENIV. The filing sets an August 10, 2026 lead plaintiff deadline and is pending in federal court in New Jersey. The article also explains the alleged revenue manipulation and the stock price losses that followed the research report.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected